Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 6, 2009, Pages 759-766

  De Gatta, María Del Mar Fernández ^a   Moreno, Silvia Romano ^b   Calvo, María Victoria ^c   Ardanuy, Ramón ^a   Domínguez Gil, Alfonso ^a,c   Lanao, José M ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Amikacin; Bayes theorem; Dosage individualization; Population pharmacokinetics

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SCREENING; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; POPULATION RESEARCH; RETROSPECTIVE STUDY; BACTERIAL INFECTION; BAYES THEOREM; CRITICAL ILLNESS; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG MONITORING; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; STATISTICAL MODEL; UNIVERSITY HOSPITAL;

AMIKACIN; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL INFECTIONS; BAYES THEOREM; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 85047684363     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.06.0008     Document Type: Article

References (39)

1. Sheiner LB et al. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445-479.
2. Mandema JW et al. Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20: 511-528.
3. Ette EI et al. Model appropriateness and population pharmacokinetic modelling. J Clin Pharmacol 2003; 43: 610-623.
4. Neef C et al. Pitfalls in TDM of antibiotic drugs: analytical and modelling issues. Ther Drug Monit 2006; 28: 686-689.
5. Sun H et al. Population pharmacokinetics. A regulatory perspective. Clin Pharmacokinet 1999; 37: 41-58.
6. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22: 447-467.
7. Duffull SB et al. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol 1997; 43: 125-135.
8. Joubert P et al. Population approach to the forecasting of amikacin plasma and urinary levels using a prescribed dosage regimen. Eur J Drug Metab Pharmacokinet 1999; 24: 39-46.
9. Gauthier T et al. Predictive performance of two software packages (USC*PACK PC and Abbott PKS system) for the individualization of amikacin dosage in intensive care unit patients. Int J Biomed Comput 1994; 36: 131-134.
10. Lugo Goytia G, Castañeda-Hernández G. Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis. Ann Pharmacother 2000; 34: 1389-1394.
11. Debord J et al. Population pharmacokinetic parameters for Bayesian monitoring of amikacin therapy in intensive care unit patients. Eur J Clin Pharmacol 1992; 43: 435-436.
12. Lugo Goytia G, Castañeda-Hernández G. Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. Ther Drug Monit 1997; 19: 271-276.
13. Romano S et al. Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients. Clin Drug Invest 1998; 15: 435-444.
14. Radomski KM et al. General versus subpopulation values in Bayesian prediction of aminoglycoside pharmacokinetics in haematology-oncology patients. Am J Health-Syst Pharm 1997; 54: 542-544.
15. McClellan SD, Farringer JA. Bayesian forecasting of aminoglycoside dosing requirements in obese patients: influence of subpopulation versus general population pharmacokinetic parameters as internal estimates. Ther Drug Monitor 1989; 11: 431-436.
16. Fernández de Gatta MM et al. Bayesian forecasting in paediatric populations. Clin Pharmacokinet 1996; 31: 325-330.
17. Goodman SN. Toward evidence-based medical statistics. 2: The Bayes Factor. Ann Inter Med 1999; 130: 1005-1013.
18. MacKay DJC. Information Theory, Inference and Algorithms. Cambridge: University Press, 2003.
19. Zellner A. An Introduction to Bayesian Inference in Econometrics. New York: Wiley and Sons, 1971.
20. Knaus WA et al. Apache II: a severity of disease classification system. Crit Care Med 1985; 13: 818-830.
21. Lacarelle B et al. Evaluation of a Bayesian Method of amikacin dosing in Intensive Care Unit patients with normal or impaired renal function. Ther Drug Monitor 1987; 9: 154-160.
22. Abbott Laboratories, Diagnostics Division. Abbottbase pharmacokinetic systems operations manual. Abbott Park, Abbott Laboratories, USA, 1993.
23. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
24. Jelliffe RW. Creatinine clearance: bedside estimate. Ann Intern Med 1973; 79: 604-605.
25. Bauer IA et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983; 24: 643-647.
26. Alvarez-Lerma F et al. Recomendaciones para la monitorizacio ́n de antibióticos en pacientes críticos ingresados en UCI. Enferm Infecc Microbiol Clin 2008; 26: 230-239.
27. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-512.
28. Craig WA. Does the dose matter? Clin Infect Dis 2001; 33 (Suppl. 3): 233-237.
29. Goldberg J, Owens RC. Optimizing antimicrobial dosing in the critically ill patient. Curr Opin Crit Care 2002; 8: 435-440.
30. Bartal C et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 2003; 114: 194-198.
31. Kaufmann GR et al. Safety and efficacy of two-compartment Bayesian feedback program for therapeutic tobramycin monitoring in the daily clinical use and comparison with a non-Bayesian one-compartment model. Ther Drug Monit 1998; 20: 172-180.
32. Böttger H et al. Use of aminoglycosides in critically ill patients: individualization of dosage using Bayesian statistics and pharmacokinetic principles. Ther Drug Monitor 1988; 10: 280-286.
33. Bacopolou F et al. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes. J Crit Care 2003; 18: 107-113.
34. Kashuba AD et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 1999; 43: 623-629.
35. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am 2003; 17: 503-528.
36. Conil JM et al. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int J Antimicrob Agents 2006; 28: 226-230.
37. Bresolle F et al. Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother 1996; 40: 1682-1689.
38. Barclay ML et al. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 1999; 36: 89-98.
39. Macdonald I et al. Evaluation and comparison of simple multiple model, richer data multiple model and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. Ther Drug Monit 2008; 30: 67-74.